Renbio, Inc.

Renbio, Inc., doing business as Renbio Inc., is a for-profit organization registered to receive awards from the U.S. federal government since February 10, 2016. The company specializes in research and development related to DNA-based delivery of antibodies, particularly in the context of rapid response platforms for infectious diseases. Renbio's expertise is focused on innovative approaches to antibody design and delivery, with applications in areas such as influenza prevention and treatment. Through its federal contract and grant awards, Renbio provides cutting-edge research and development services to government agencies, primarily in the field of biotechnology and medical countermeasures.

Renbio's most recent federal contract award demonstrates the nature of work the company performs via contracts. On April 29, 2024, Renbio received a $749,289.42 firm fixed-price definitive contract from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response. This contract, set to be completed by July 1, 2025, involves research and development on DNA-based delivery of anti-influenza antibodies to large animals under AOI#25 (FASTX) for myo technology. The contract was awarded without any set-aside designation, indicating that Renbio competed in an unrestricted procurement process. This award highlights Renbio's capability to conduct advanced research in antibody delivery systems, specifically targeting influenza prevention and treatment strategies.

In addition to its contract work, Renbio has been involved in federal grant sub-awards, which further illustrate the company's research focus and capabilities. Renbio has participated in projects focused on designing and testing DNA-based antibody delivery constructs as part of a rapid response platform. These sub-awards were related to a project titled "RRADD: Rapid Rational Antibody Design and Delivery." One of the sub-awards was associated with Vanderbilt University Medical Center as the prime grantee, suggesting collaborative efforts between Renbio and academic institutions in advancing antibody delivery technologies. While specific details about the grant program and funding agency are not provided in the given information, these grant-funded projects demonstrate Renbio's continued involvement in cutting-edge research aimed at developing innovative solutions for rapid antibody design and delivery systems. The collaboration with a prominent academic institution also underscores Renbio's position as a valuable partner in pioneering biotechnology research.